This dual-action property of targeting the core therapeutic target (GSK3β) while also inhibiting a key inflammatory pathway (p38 MAPK) makes curcumin a highly promising drug candidate, potentially offering a safer and more comprehensive solution for the complex clinical challenge of treating BD and T2D comorbidity. Here, GSK3B is linked to Behcet disease.